Business
Karyopharm Names New Head of Investor Relations
– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations –\n– Webb Brings More than 20 Years of Diverse International Experience Across Investor Relations, Business Development, Investment Analysis and Portfolio Management in the Healthcare and Biotechnology Fields –\nNEWTON, Mass., March 14, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Elhan Webb as Senior Vice President of Investor Relations. \n\"Elhan brings tremendous experience with sell-side and buy-side analysts, as well as a robust network from across the biotechnology financial and investment community to Karyopharm,\" said Richard Paulson, President and Chief Executive Officer of Karyopharm. \"Elhan has a proven track record of building best-in-class investor relations functions, and she will leverage this expertise to drive awareness and understanding of Karyopharm's strong portfolio, pipeline and vision for the future. We are thrilled to have her as part of the team.\"\nMs. Webb brings more than 20 years of experience to her new role. Most recently, she served as Vice President of Investor Relations at Rubius Therapeutics. Previously, she was responsible for heading investor relations at Radius Health and Genfit. During her time at Roche Investor Relations, Ms. Webb led Investor Relations activities for Roche Diagnostics. She also held business development roles at Roche Molecular Diagnostics and Morphochem. Earlier in her career, Ms. Webb spent more than a decade in Europe managing and leading investments in the healthcare sector at financial institutions such as BB Biotech-Bellevue Asset Management, Cantrade-UBS and Lombard Odier.\nMs. Webb has a Masters in Business Administration from the University of Southern California and an undergraduate degree in Economics from Bogazici University in Istanbul, Turkey. She is also a CFA Charterholder.\nAbout Karyopharm Therapeutics\nKaryopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamen...